

### SIGACHI INDUSTRIES LIMITED

CIN: L24110TG1989PLC009497

To, Date: January 18, 2025

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 543389)
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051.
(NSE Symbol: SIGACHI)

Dear Sir/Madam,

#### **Sub: Investor Presentation for Q3 FY 2024-25**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015, and with reference to the subject cited, please find enclosed the Investor Presentation for Q3 FY 2024-25. The same is also uploaded on the website of the Company <a href="https://www.sigachi.com">www.sigachi.com</a>

This is for the information and record of the exchanges.

Thanking You,

Yours faithfully

For Sigachi Industries Limited

Vivek Kumar

Company Secretary & Compliance Officer



#229/1 & 90, 2nd Floor, Kalyan's Tulsiram Chambers, Madinaguda, Hyderabad-49, Telangana State, India. Customer Service +91 40 40114874-76, E-mail: info@sigachi.com, URL: www.sigachi.com





## SIGACHI INDUSTRIES LTD

Q3 & 9MFY25
Investor Presentation

January'2025

### Safe Harbour



No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Sigachi Industries Limited (hereinafter referred to as "Sigachi" or "Company"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from. This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.



# Agenda



01.

**Operational & Financial** Highlights

03.

Competitive Edge

02.

**Business Overview** 

04.

**Annexure** 

## **About Sigachi**





### VISION

To contribute towards creating **Healthier**, **Happier** and Joyful World while living Sigachi values-Respect, Integrity, Resourcefulness and Excellence





**OF INDUSTRY LEADERSHIP** 

**WE ARE ONE OF THE** 

### LARGEST **MANUFACTURERS**

**OF CELLULOSE-BASED EXCIPIENTS** 





**Excellence** 





Respect



**MISSION** 

To ensure all our stakeholders i.e., Customers, Suppliers, Employees, Shareholders and the Planet Earth "Experience Excellence" with everything we do **GLOBAL REACH** 

**COUNTRIES** 

**SATISFIED CUSTOMERS** 

**PRODUCT RANGE** 


**HIGH-PERFORMANCE EXCIPIENTS** 



### PRODUCT AND SERVICE OFFERINGS



**EXCIPIENTS** 







FOOD & NUTRITION



**OPERATIONS &** MANAGEMENT



**FILM COATINGS** 



**POLYMER BLENDS** 





### A Trusted Global Partner in Excipients, APIs, and Beyond



We are more than just a supplier; we are a strategic partner committed to delivering excellence, fostering sustainable growth, and supporting clients across diverse sectors. Our growth across Pharma Excipients, APIs, Nutraceuticals, Cosmetics and Food Ingredients are driven by innovation, sustainability, and a customer-first approach.



Mr. Amit Raj Sinha MD & CEO

## **Our Core Strengths and Capabilities**





Global Presence



Manufacturing Facilities



Production Capacity



Product Range




500 + Customers across 65+ Countries

5 State of the art facilities, strategically located in Hyderabad, Sultanpur,
Jhagadia, Dahej & Raichur

Operating at a combined capacity of 21,700 MTPA across 3 strategic locations

Offering 100+ Products alongside tailored, customer centric solutions

Delivering consistent quality and tailored solutions to meet the evolving needs of our customers.




**Employees** 

## **Core Business More Than Doubled in 5 Years**



### MCC Revenue Grew 2.6x





## **Operational and Financial Highlights**

**Business Overview** 

Competitive Edge Driving Profitability and Financial Stability

Annexure

## **Business Update- Q3 & 9MFY25**





Achieved GAIN (Global Alliance for Improved Nutrition) Audit

Certification

Its **Sultanpur, Hyderabad facility** was approved by Intertek on behalf of GAIN

Reinforces Sigachi's commitment to quality and leadership in food and nutrition




Committed to R&D Excellence


Focused on enhancing R&D and cost-effective manufacturing

Striving to remain the preferred manufacturer with top-quality standards.

### **Other Updates**

- Strategic entry into coatings market to harness growth potential
- Expertise in pharmaceutical formulations drives innovation.
- State-of-the-art facilities ensure superior product quality





## **ESG Performance Q3 & 9MFY25**



### **Progressing Towards A BETTER TOMORROW, Operating Responsibly Growing Sustainably**



## Environment (FY23-24)

- Reducing our impact on the environment
- Reduced 7.65% in Total Carbon Emissions
- Recycled and Reused 81.25% of the total waste generated



#### Social

### **Social Employee Wellbeing**

- Great Place To Work® Certified
- 74 new hires (Q3)
- 19% gender diversity (Q3)
- 0 fatalities

### **Corporate Social Responsibility**

 Over 12,600+ lives touched in India through CSR initiatives



Governance (FY23-24)

#### **Corporate Governance**


- 100% Average Board meeting attendance
- 50% Independent board directors



Shareholders: Uninterrupted Value creation by Multiple diverse Business Verticals in the conglomerate



**Customers:** Increased trust on brands and Products owing to respected customer-first global avatar






community: Larger expenditure towards CSR & Significant increase in ESG focus to achieve sustainability goals



## **Q3FY25** Financial Highlights





Rs. 1,394 Mn

25.70 % YOY

PAT (Rs. Mn)

Rs. 205 Mn

**1** 26.54 % YOY



Rs. 332 Mn

46.90 % YOY




**EBITDA: 23.81%** 

343 bps (YoY)


**PAT: 14.70%** 

9 bps (YoY)



## **9MFY25** Financial Highlights





Rs. 3,721 Mn



26.22 % YOY



Rs. 542 Mn



29.04 % YOY



Rs. 835 Mn



38.47 % YOY




**EBITDA: 22.44%** 

199 bps (YoY)

**PAT: 14.56%** 


32 bps (YoY)



<sup>\*</sup> Includes Revenue from PLI

## Q3 & 9MFY25 Story in Charts






## **Uptick in MCC Quantity**








## Revenue Growth in MCC (Rs.Mn)





### **Key Drivers**


Revenue in MCC Experienced Robust Growth

Attributed to Increased Demand and Ramp up in Capacity Utilization

Average Price of MCC for the 9M FY25 was at Rs 212.97 per kg

## Revenue Growth in O&M (Rs.Mn)





### **Key Drivers**

 Revenue Growth is mainly attributable to increase in customers.

## **Strategic Alliance to Drive Expansion-JVs**





### **Expansion in UAE**





### **Strategic Growth in Saudi Arabia**



### **Formation of Sigachi Global Joint Venture**

- Partnership Structure: Sigachi MENA FZCO, a wholly owned subsidiary of the company, partners with iConsult Trading Consultancy LLC, a subsidiary of iMass Investments, UAE, forming a joint venture named Sigachi Global
- Market Focus: The JV aims to enter and expand in the UAE's growing food and pharmaceutical sectors, leveraging the region's market potential.
- Ownership Stake: Sigachi MENA FZCO will hold a 75% stake in Sigachi Global, while iConsult will retain a 25% stake.




### Sigachi Arabia Joint Venture

- Partnership Structure: Sigachi Arabia, a JV between Sigachi MENA FZCO and Saudi National Projects Investment Limited (SNP Global)
- Revenue Sources: Revenue is expected primarily from Saudi Government Tenders and partnerships with large corporate clients
- Local Market Leverage: By establishing a local presence, Sigachi Arabia is positioned to capitalize on emerging opportunities within the Saudi market.
- Ownership Stake: Sigachi MENA FZCO holds a 75% stake in Sigachi Arabia, with SNP holding 25%.

## **Strategic Priorities and Way Forward**





**MCC** 

Enhanced Utilization:
 Striving for 80% Capacity
 Utilization of added
 Capacity by FY26

### **Market Expansion**

- Geographic Expansion: Deepen market penetration with existing customers and expand into new regions
- Paraden Market Footprint:
  Target B2B growth in human
  nutrition and expand excipient
  exports across 60 countries

### API

- Portfolio Integration:
   Seamlessly incorporate the new
   API unit with existing excipient offerings for a comprehensive customer solution
- Enter Regulated Market:

   Pursuing EU Approvals and
   Securing 9 CEPs in FY25 for
   Critical APIs to enter Regulated
   Market

#### CCS

 Commercializing CCS: Aim to commercialize CCS within 18 months.

#### **0&M**

 Advanced O&M Services: Focus on specialty chemicals, petrochemicals, water treatment, and pharma plants, leveraging industry 4.0 technologies for enhanced efficiency and compliance

## **Income Statement** Q3 & 9MFY25



Particulars (Rs. Mn)	Q3FY25	Q3FY24	YoY	Q2FY25	QoQ	9MFY25	9MFY24	YoY
Revenue from Operations*	1,394	1,109	25.70%	1,370	1.75%	3,721	2,948	26.22%
Total Expenses	1,062	883	20.27%	1,077	(1.39)%	2,886	2,345	23.07%
EBITDA	332	226	46.90%	293	13.31%	835	603	38.47%
EBITDA Margin	23.81%	20.38%	343 Bps	21.38%	243 Bps	22.44%	20.45%	199 Bps
Depreciation and Amortization	47	28		32		110	73	
Finance Cost	38	18		21		91	49	
Other Income	20	17		25		62	44	
PBT	267	197	35.53%	265	0.75%	696	525	32.57%
PBT Margin	19.15%	19.33%	(18) Bps	21.22%	(207) Bps	18.70%	17.80%	90 Bps
Tax Expense	62	35	77.14%	55	12.72%	154	105	46.67%
PAT	205	162	26.54%	210	(2.38)%	542	420	29.04%
PAT Margin	14.70%	14.61%	9 Bps	16.81%	(211) Bps	14.56%	14.24%	32 Bps
Other Comprehensive Income	1	(1)		1		3	(1)	
Total Comprehensive Incomes	206	161	27.96%	211	(2.36)%	545	419	30.07%
Basic EPS (Rs Per Share)	0.65	0.51	30.00%	0.66	(1.51)%	1.71	1.35	26.67%
Diluted EPS (Rs Per Share)	0.52	0.43	20.93%	0.63	(17.46)%	1.37	1.13	21.23%



Operational and Financial Highlights

**Business Overview** 


Competitive Edge Driving Profitability and Financial Stability

**Annexure** 

## **Sigachi Industries – Distinct Value Proposition**




**Sigachi Industries Ltd: Leading Manufacturer of Pre-Formulation Excipients** 



## **Present Across the Pharma Ecosystem**




### **Pharma & Formulations**



## One of the Largest Manufacturers of MCC in the World



Maximizing Capacity: Efficient Utilization (9M FY25)



The capacity (7,200 MTPA) added in Q4FY24 resulted in an increase to total capacity of 21,700 MTPA

Leading MCC
Manufacturer
in India

Operating at a combined capacity of 21,700 MTPA across 3 strategic locations


Expanded capacity has achieved 25% utilization in 9MFY25

Anticipated annual growth in capacity utilization: 20%-25% YoY

### **Robust Growth in O&M Business**



### **Revenue Tripled**



### **Trusted Partners**

- Gujarat Alkalies
- Aditya Birla Group
- ONGC Petro Additions
- Lords Chloro Alkali Limited


### **Asset Light Model**

- Zero Capex Requirement
- Contracts Win to Boost RoE and

### **Research & Product Excellence**



### **Advanced Manufacturing Facilities across 5 Strategic Locations**





Quality Assurance through Cutting-edge Facilities, Expert R&D, Accreditation and USFDA approved facility for Manufacturing Critical & Advanced intermediates. DMF for Coatings

#### **Manufacturing Units**

 Five manufacturing facilities (Telangana, Gujarat, Karnataka) including SEZ and dedicated nutritional premix facility.

#### **Research and Development**

 Two state-of-the-art R&D labs located in Dahej and Jhagadia focusing on performance-oriented approaches and in-house technologies

#### **Expansion Plans**

- Expanding Dahej, Jhagadia Capacities for MCC;
- Setting up New Dahej Unit for CCS

#### **Accredited Laboratory**

 Laboratory at Jhagadia accredited by Department of Science and Industrial Research (DSIR).

## **Ongoing Commitment to R&D Investment**



**Trademarks** 


46

**Patent Filed** 

7

**CEP** 

4



## **Quality Assurance: Certifications & Accreditation**





























Operational and Financial Highlights


**Business Overview** 


**Competitive Edge Driving Profitability** and Financial Stability


**Annexure** 

## **Achieving 3x Growth in Revenue and PAT**











Margin	5 Years CAGR	5 Year Average Margin
EBITDA	24%	19.6%
PAT	25%	14.9%

Nos. are consolidated basis

## **Sustainable Margins**









## **Low Debt: Maximizing Financial Stability**








## **Cash Flow**



### **To Drive Future Growth**





Operational and Financial Highlights

**Business Overview** 

Competitive Edge Driving Profitability and Financial Stability

**Annexure** 

## **Historical Income Statement**



Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	9MFY25
Revenue from Operations*	1,928	2,503	3,020	3,989	3,721
Total Expenses	1,540	1,972	2,433	3,223	2,886
EBITDA	388	531	587	766	835
EBITDA Margin	20.12%	21.21%	19.43%	19.20%	22.44%
Depreciation and Amortisation	23	29	66	108	110
Finance costs	13	12	43	78	91
Other Income	33	26	67	117	62
PBT	385	516	545	697	696
PBT Margin	20.0%	20.6%	18.0%	17.47%	18.70%
Tax Expense	82	116	109	125	154
PAT	303	400	436	572	542
PAT Margin	15.72%	15.98%	14.43%	14.34%	14.56%
Other Comprehensive Income	1	-6	1	-	3
Total Comprehensive Income	304	394	437	572	545
Basic EPS	1.31	1.54	1.41	1.81	1.71
Diluted EPS	1.31	1.54	1.41	1.54	1.37

## **Historical Balance Sheet**



Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	H1FY25
NON-CURRENT ASSETS	463	1,069	1,964	3,809	3,911
a) Property, plant and equipment	376	527	960	1,711	2,757
b) Capital work-in-progress	37	97	349	966	82
c) Intangible assets	3	7	7	14	14
d) Goodwill	-	-	-	547	547
e) Right of Use Assets	-	-	257	277	287
f) Financial assets					
i) Investments	2	2	2	3	3
ii) Other Financial Assets	18	351	225	199	206
g) Other non-current assets	27	85	164	92	16
CURRENT ASSETS	871	1,799	1,774	3,133	3,616
a) Financial Assets					
i) Trade Receivables	358	601	802	1,500	1,723
ii) Cash and cash equivalents	159	291	137	174	82
iii) Bank balances other than above	21	403	190	396	398
iv) Other financial assets	100	128	69	163	285
b) Other current assets	21	71	110	192	216
c) Inventories	212	305	466	707	911
TOTAL ASSETS	1,334	2,868	3,738	6,942	7,527

## **Historical Balance Sheet**



			CAL				
Particulars (Rs. Mn)	FY21	FY22	FY23	FY24	H1FY25		
EQUITY	942	2,277	2,683	4,410	4,820		
Equity Share Capital	77	307	307	328	333		
Other Equity	865	1,970	2,376	3,968	4,384		
Equity attributable to the owners of the company	942	2,277	2,683	4,296	4,717		
Minority Interest	-	-	-	114	102		
NON-CURRENT LIABILITIES	70	76	308	653	759		
a) Financial Liabilities							
i) Borrowings	19	12	10	266	326		
ii) Lease Liability	-	-	231	205	229		
b) Provisions	8	9	15	18	15		
c) Deferred tax liabilities (net)	43	55	52	164	189		
CURRENT LIABILITIES	322	515	747	1,878	1,948		
a) Financial Liabilities							
i) Borrowings	183	332	395	924	1,022		
ii) Lease Liabilities	-	-	41	36	24		
iii) Trade Payables	80	106	208	479	500		
iv) Other financial liabilities	7	6	9	80	71		
b) Other current liabilities	43	59	94	335	312		
c) Current tax liabilities (Net)	9	12	-	24	20		
TOTAL LIABILITIES	392	591	1,055	2,531	2,707		
TOTAL EQUITY AND LIABILITIES	1,334	2,868	3,738	6,942	7,527		

## **Key Milestones**



### 2000

### 1989

Incorporated as 'Sigachi Chloro-Chemicals Private Limited

- Launched premium-grade
   MCC production
- Installed advanced spray drier and multi-fuel furnace
- Capacity boosted from 720 to 1080 MTPA

#### 2010

Commenced the commercial production of MCC at manufacturing unit situated at Jhagadia

#### 2014

Merger of Sigachi Cellulose Private Limited and Sigachi Plasticizers Private Limited with the company

#### 2023

Expanded Capacity to 21,000 MTPA, the Largest MCC Manufacturing Company in India

#### 2024

Sigachi MENA FZCO, a wholly owned subsidiary, has announced the formation of joint ventures, Sigachi Arabia and Sigachi Global.



### 1998

Commenced its export operations by exporting its product

#### 2009

Setting up of 100 % export oriented unit ("EOU") for manufacturing MCC in the SEZ at Dahej, Gujarat

#### 2012

Commenced the
Commercial production
of MCC at the
manufacturing unit
situated at Dahej

#### 2021

Got listed on NSE & BSE on Nov 15, 2021

#### 2023

market.

Acquired Trimax Biosciences Pvt Ltd to expand into API product offerings

Sigachi MENA FZCO, a wholly owned subsidiary, has formed a joint venture with Saudi National Projects Investment (SNP) to enter the growing Saudi Arabian

### 2025

Achieved GAIN (Global Alliance for Improved Nutrition) Audit Certification

## **Strong Leadership**



# Distinct, high performing businesses aligned with business drivers and market requirements



Rabindra Prasad Sinha Whole Time-Director & Chairman



Shanmuganathan
Whole Time-Director &
Vice Chairman



Amit Raj Sinha Managing Director & CEO



**Lijo Chacko** CEO Sigachi MEA



Subbarami Reddy Oruganti Chief Financial Officer



### SIGACHI INDUSTRIES LTD

# **THANK YOU!**

### **Corporate Office:**

Plot No. G 57/2, Survey no.70 C 174, Sultanpur Village, Patancheru Mandal, Hyderabad 502319, Sanga Reddy District, Telangana, India. Landline +918455242055/56/57



2nd floor, Kalyans Tulsiram Chambers, Madinaguda, Hyderabad 500049, Telangana, India. Landline +9140 40114874 /75/76

### **GO INDIA ADVISORS – IR FIRM**

Ms. Priya Sen

priya@goindiaadvisors.com

M: +91 8334841047

Ms. Sana Kapoor

sana@goindiaadvisors.com

M:+91 8146550469

Ms. Sheetal Khanduja

sheetal@goindiaadvisors.com

M: +91 9769364166